ECOG Pathology Coordination Office - Reference Laboratory: E2208 Randomized Phase II Study of Paclitaxel with or without the Anti-IGF-IR nAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients with Metastatic Esophageal or GE Junction Cancer